King's College London has developed an experimental drug that improves the response of chemotherapy-resistant tumors by targeting a tumor defense protein.
Ana Maria Eftene
International
Foto: Pexels.com
Always see our news on Google
The drug KCL-HO-1i developed by researchers at King's College London has the potential to transform treatments for chemotherapy-resistant cancers. It works by neutralizing the protein heme oxygenase-1 (HO-1), which helps tumors protect themselves from chemotherapy and immune system attacks. Preclinical tests have shown that the drug can make tumors more responsive to chemotherapy, even in previously resistant cases. Designed for oral administration, KCL-HO-1i could begin human clinical trials in two years, with the potential to expand its applications in oncology.
Sources
Speranță pentru bolnavii de cancer: Un nou medicament sporește eficacitatea chimioterapiei chiar și în cazul tumorilor rezistente
A apărut pastila care dezarmează cancerul! Descoperirea care ar putea rescrie regulile chimioterapiei: Chiar și cele mai rezistente tumori răspund la tratament
Latest News
17:35
The Ministry of Energy denies the information according to which large industrial consumers have received notifications to limit energy consumption.
17:30
A 59-year-old woman from Oradea won the largest prize in the history of Loto 6/49, worth 10 million euros.
17:18
Liberia announces that it will accept up to 1,200 foreign nationals expelled from the USA, as part of a program initiated by Donald Trump.
17:15
CSM contests the salary positioning of the president of the ICCJ below ministers and presidential advisors
17:09
ISU Harghita identified 82 mortar bombs in the forest of Tușnad Nou. The firefighters intervened with a bomb disposal team to remove them.
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
